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The rapidly increasing use of allogeneic stem cell transplantation (allo-SCT) emphasizes the need for iden-
tifying variables predictive of its outcome. Plasmacytoid dendritic cells (pDCs) play a major role in estab-
lishing immune competence and in several autoimmune diseases. Thus, we investigated whether pDCs might
inﬂuence the outcome of patients after allo-SCT in 79 consecutive patients who underwent this procedure.
pDCs were identiﬁed in the blood of patients at day 100 after allo-SCT by staining peripheral blood mono-
nuclear cells for surface markers and intracellular cytokines and analyzing them on a ﬂow cytometer. We
found the pDC level at day 100 was not inﬂuenced by patient or graft characteristics, and only the absence of
previous grades II to IV acute graft-versus-host disease was signiﬁcantly associated with higher levels of
blood pDCs after allo-SCT (OR, .67; 95% CI, .54 to .83; P ¼ .0004). Using the median value of pDCs at day 100 to
divide the patients into 2 distinct groups, we observed that a low pDC level was correlated with a worse
overall survival (55% versus 86%, P ¼ .007). In a multivariate analysis, only low pDC level (OR, 3.41; 95% CI, 1.19
to 9.79; P ¼ .02) and older patient age (OR, 5.16; 95% CI, 1.15 to 23.14; P ¼ .03) were signiﬁcantly predictive of
increased risk of death. We conclude that monitoring of pDC may be useful for patient management and may
have a signiﬁcant impact on the probability of a favorable outcome of allo-SCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION present host antigens to donor T lymphocytes. Among DC
Allogeneic stem cell transplantation (allo-SCT) has evolved
into a curative therapy for a variety of hematological and
nonhematological malignancies. In the treatment of the
former, high-intensity conditioning therapy before allo-SCT
eradicates malignant cells, and the infusion of donor stem
cells enables reconstitution of the recipient’s hematopoietic
system and also triggers a graft-versus-leukemia (GVL) effect.
However, the main limitation of treating a broader spectrum
of diseases and patients with allo-SCT is graft-versus-host
disease (GVHD), a reaction closely associated to GVL.
Both GVHD and GVL occur when donor T lymphocytes
respond to genetically deﬁned proteins on host cells. Den-
dritic cells (DCs) are key antigen-presenting cells thatdgments on page 1435.
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ty for Blood and Marrow Transplantation.subsets, plasmacytoid DCs (pDCs) have been proposed to
play a major role in induction and regulation of immune
responses. pDC activated through Toll-like receptors (TLRs)
rapidly secrete massive amounts of IFN-a and induce im-
mune responses through activation of effector T lymphocytes
[1]. On the contrary, unstimulated or alternatively stimulated
pDCs can alleviate protective immunogenic responses
through the induction of T regulatory lymphocytes [2,3].
Previous studies established the role of pDCs in the patho-
physiology of several autoimmune diseases [4-6]. The inﬂu-
ence of these cell populations in GVHD and GVL is, however,
controversial [7-10] and probably depends on their activa-
tion state, distribution, and migration patterns.
The rapidly increasing use of allo-SCT emphasizes the
need for clinical research aimed at identifying variables
predictive of outcome of patients. Therefore, we investigated
the impact of circulating pDCs measured at 100 days after
allo-SCT in 79 patients to evaluate the role of these cells in
GVHD and GVL and their impact on long-term outcome.
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Study Design
Seventy-nine consecutive patients treated with allo-SCT in a single
center (Centre Hospitalier Universitaire de Nantes) with a minimal follow-
up of 6 months were included in this analysis. Written informed consent
was obtained from each patient and donor. The studies were approved by
the local ethics committee and performed according to institutional
guidelines. Patient, donor, and graft characteristics are summarized in
Table 1.
Transplant Procedures
Most patients (89%) were treated with reduced-intensity conditioning
allo-SCT. The reduced-intensity conditioning regimen was mainly based on
30 mg/m2 ﬂudarabine daily over 4 to 6 days, 3.2 mg/kg i.v. busulfan daily
over 2 to 3 days, and 5 mg/kg antithymocyte globulin (Thymoglobulin;
Genzyme, Lyon, France) infused over 2 days [11]. GVHD prophylaxis was
mostly carried out with cyclosporine A alone or with cyclosporine A and
mycophenolate mofetil. Most patients received a peripheral blood stem cell
allograft mobilized with granulocyte colony-stimulating factor in a dose of
10 mg/kg/day for 5 days.
pDC Analysis
All blood samples were collected in EDTA tubes at day 100 after allo-SCT.
Peripheral blood mononuclear cells (PBMCs) were isolated by density
gradient centrifugation and then cryopreserved in .5-mL aliquots at 80C.
At the time of analysis, PBMCs were thawed and stimulated for 6 hours
with TLR7 ligands (5 mg/mL R848; Invivogen, Toulouse, France) and TLR9
ligands (10 mg/mL CpGA2216; Invivogen), in the presence of 10 ng/mL IL3
(Peprotech, Tebu-bio, Le Perray-en-Yvelines, France), cytokine important for
pDC survival. Two hours after the beginning of stimulation, 10 mg/mL Bre-
feldin A (Sigma-Aldrich, Saint-Quentin Fallavier, France) was added to stop
the extracellular secretion of cytokines. For surface markers, cells were
stained according to manufacturer’s protocol with conjugated antibodies
Paciﬁc Blue HLA-DR and Pe-Cy7 CD123 (both from Biolegend, Ozyme, Saint-Table 1
Baseline Demographic Characteristics of Low pDC vs. High pDC Group and the Wh
Characteristic Low pDC (n ¼ 32)
Patient age, median (range) 54 (26-71)
Patient gender
Male 18 (55)
Female 14 (45)
Diagnosis*
Myeloid malignancy 13 (41)
Lymphoid malignancy 18 (56)
Aplastic anemia 1 (3)
Disease risky
Standard risk 13 (41)
High risk 19 (59)
Conditioning regimen
Myeloablative 3 (9)
RIC 29 (91)
GVHD prophylaxis
CsA alone 8 (25)
CsA and MMF/MTX 24 (75)
Donor gender
Male 17 (53)
Female 15 (47)
CMV seronegative pair
Yes 9 (28)
No 23 (72)
Donor type
Matched related donor 10 (31)
Matched unrelated donor 12 (38)
Mismatched unrelated donor 10 (31)
Stem cell source
Bone marrow 5 (16)
Peripheral blood 20 (63)
Cord blood 7 (21)
Median cells infused, 106/kg (range) 6 (.06-10.10)
RIC indicates reduced-intensity conditioning; CsA, cyclosporine A; MMF, mycophe
Values are number of cases with percents in parentheses, unless otherwise noted.
* Myeloid malignancies in all patients included 28 acute myeloid leukemias, 10
myeloid leukemias. Lymphoid malignancies included 13 non-Hodgkin lymphoma
phocytic leukemias, and 2 Hodgkin lymphomas.
y Standard risk disease: acute leukemia in ﬁrst complete remission, chronic myeQuentin en Yvelines, France) and APC BDCA2 (Miltenyi, Paris, France). Cells
were ﬁxed and permeabilized using Cytoﬁx/Cytoperm reagents (BD
Biosciences, Le Pont de Claix, France) and then incubated with PE IFN-a
(Miltenyi), FITC IL-6 (Biolegend), and PerCp-Cy5.5 tumor necrosis factor
(TNF)-a (Biolegend). Finally, cells were analyzed on a FACSCanto II using
DIVA software (BD Biosciences).
Clinical Outcomes and Statistical Methods
Acute GVHD was evaluated according to standard Seattle criteria [12].
Upon diagnosis of grades II to IV acute GVHD, all patients were primarily
treated with cyclosporine A and 2 mg/kg/d methylprednisolone. Acute and
chronic GVHD were arbitrarily separated by day 100 after allo-SCT. Chronic
GVHD was clinically evaluated as limited or extensive. When the latter was
diagnosed, patients were treated with 1 mg/kg/d methylprednisolone [13].
Data were computed using the R package (R Foundation for Statistical
Computing, http://www.R-project.org) TheMann-Whitney test was used for
comparison of continuous variables. Categorical variables were compared by
the chi-square or Fisher’s exact test. The probability of developing acute and
chronic GVHD was calculated by the cumulative incidence treating death as
a competitive risk [14]. Cumulative incidence estimates were also used to
measure relapse. Probabilities of overall survival (OS) were assessed from
the time of transplantation using the Kaplan-Meier product-limit estimates.
Differences between groups were tested using the log-rank test. A multiple
logistic regression with backward stepwise model selection was used to
uncover predictive factors for cell recovery at 100 days after allo-SCT. The
association of OSwith cell counts and other relevant variables was evaluated
in a multivariate analysis using Cox’s proportional-hazard regression model.
RESULTS
Transplant related events and outcomes from our study
are summarized in Table 2. The OS at 2 years was 74% (95%
conﬁdence interval [CI], 64% to 86%), with amedian follow up
of 592 days (range, 225 to 873 days) for living patients. Theole Study Population
High pDC (n ¼ 47) All Patients (n ¼ 79) P
54 (27-69) 54 (26-71) .65
.65
24 (51) 42 (53)
23 (49) 37 (47)
.10
29 (62) 42 (53)
17 (36) 35 (44)
1 (2) 2 (3)
.98
19 (40) 32 (41)
28 (60) 47 (59)
.64
6 (13) 9 (11)
41 (87) 70 (89)
.22
18 (38) 26 (33)
29 (62) 53 (67)
.18
32 (68) 49 (62)
15 (32) 30 (38)
.87
14 (30) 23 (29)
33 (70) 56 (71)
.06
27 (57) 37 (46)
13 (28) 25 (32)
7 (15) 17 (22)
.52
5 (11) 10 (12)
35 (74) 55 (70)
7 (15) 14 (18)
4.98 (.07-10.00) 5.25 (.06-10.10) .17
nolate mofetil; MTX, methotrexate; CMV, cytomegalovirus.
myelodysplastic syndromes, 3 myeloproliferative syndromes, and 2 chronic
s, 9 acute lymphoblastic leukemias, 7 multiple myelomas, 3 chronic lym-
loid leukemia in chronic phase, and untreated disease; all others-high risk.
Table 2
Transplant-Related Events and Outcome of Low pDC vs. High pDC Groups
Characteristic Low pDC (n ¼ 32) High pDC (n ¼ 47) All Patients (n ¼ 79) P
Neutrophil recovery
Median ANC > .5  109/L (range) 17 (11-32) 16 (8-43) 16 (8-43) .28
Acute GVHD <.0001
Grades 0-I 13 (41) 39 (83) 52 (65)
Grades II-IV 19 (59) 8 (17) 27 (35)
Median acute GVHD onset after transplantation, days (range) 29 (13-97) 32 (8-91) 30 (8-97) .56
CMV antigenemia before 100 days after allo-SCT .09
No 24 (75) 42 (89) 66 (84)
Yes 8 (25) 5 (11) 13 (16)
Median blood cell counts/mL at day þ100 (range)
Leukocytes 4900 (1700-16,400) 4300 (1000-13,100) 4650 (1000-16,400) .18
Granulocytes 3200 (800-14,600) 2400 (60-8300) 2570 (60-14,600) .11
Lymphocytes 800 (100-5200) 1000 (120-2900) 940 (100-5200) .18
Monocytes 400 (20-1600) 500 (20-1500) 500 (20-1600) .64
CD4þ 90 (1-650) 130 (20-980) 114 (1-980) .13
CD8þ 140 (20-2700) 310 (20-2400) 266 (20-2700) .24
Chronic GVHD .26
No or limited 20 (63) 35 (74) 55 (70)
Extensive 12 (37) 12 (26) 24 (30)
Median chronic GVHD onset after transplantation, days (range) 127 (100-546) 137 (101-379) 134 (100-546) .49
Median follow up for surviving patients, days (range) 638 (225-825) 626 (384-873) 592 (225-873) .72
ANC indicates absolute neutrophil count.
Values are number of cases with percents in parentheses, unless otherwise noted.
P = ,002
P = ,0005
A
B
Figure 1. Detection of IFN-a and TNF-a producing pDCs after CpGA stimula-
tion according to acute GVHD (aGVHD) grade. (A and B) Total PBMCs were
stimulated with CpG2216, and intracellular IFN-a and TNF-a were analyzed by
ﬂow cytometry by gating on BDCA2 and CD123 positive cells. Results are
indicated for each individual patient and mean  SEM of the percentage of
IFN-a (A) and TNF-a (B) positive cells is indicated by a bar.
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activation with TLR ligands was .2% of PBMCs. We used this
value to allocate the patients to a “low pDC” (<.2% of PBMCs)
or “high pDC” (.2% PBMCs) recovery group. Baseline de-
mographic and transplant characteristic of these 2 groups
werecomparable andare shown inTable1. Transplant-related
events and patient outcomes of the low pDC and high pDC
recovery groups were also similar (Table 2), except for the
incidence of acute GVHD. Namely, clinically signiﬁcant grades
II to IV (moderate to severe) acute GVHD occurred in 27 cases
(33%) at amedian of 30 days after allo-SCT, and this accounted
for 19 patients (59%) in the low pDC but only 8 patients (17%)
in the high pDC recovery group (P < .0001).
Therefore, we built a multivariate logistic regression
model for pDC recovery in the blood of patients at day 100
after Allo-SCT. All variables with P < .20 in the univariate
analysis were included in the model (diagnosis, donor
gender and type, cytomegalovirus antigenemia and acute
GVHD). A backward stepwise selection was performed and
yielded a model with 2 variables: matched unrelated donor
(odds ratio, .84; 95% CI, .68 to 1.03; P¼ .09) and occurrence of
grades II to IV acute GVHD (odds ratio, .67; 95% CI, .54 to .83;
P ¼ .0004). Finally, only the presence of clinically signiﬁcant
grades II to IV acute GVHD was signiﬁcantly associated with
an impaired pDC recovery at day 100 after allo-SCT.
Furthermore, we observed that the proportion of pDC
producing IFN-a or TNF-a was signiﬁcantly increased in pa-
tients with grades 0 to I acute GVHD in comparison with
patients with clinically severe grades II to IV acute GVHD (P¼
.002 and P ¼ .0005, respectively) (Figure 1A and B). In
contrast, when patients treated with high doses of cortico-
steroids were excluded from the analysis, we did not observe
any signiﬁcant difference in the secretion of IFN-a and TNF-a
from activated pDCs between patients with and without
clinically severe GVHD.
The cumulative incidence of extensive chronic GVHD
in our study group was 37% (95% CI, 25% to 49%) at 20
months, with this incidence higher in the low pDC (44%; 95%
CI, 24% to 63%) than in the high pDC group (30%; 95% CI, 17%
to 46%); however, this difference was not statistically
AB
P = .25
P = .018
Figure 2. (A) Cumulative incidence of extensive chronic GVHD (cGVHD) at 20 months after allo-SCT according to the low pDC versus high pDC group. (B) Cumulative
incidence of relapse-related mortality at 20 months after allo-SCT according to the low pDC versus high pDC group. pDC recovery groups determined at 100 days after
allo-SCT. Solid lines indicate low pDC recovery group; dashed lines, high pDC recovery group.
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number of deaths related to relapse in the low pDC group
(35%; 95% CI, 16% to 54%) compared with the high pDC group
(9.5%; 95%, CI 3% to 21%; P¼ .0018) (Figure 2B). Moreover, the
high pDC group showed signiﬁcantly better OS (86%; 95% CI,
76% to 97%) than those in the low pDC group (55%; 95% CI,
38% to 80%; P ¼ .007) (Figure 3). Finally, a multivariateanalysis was done to identify predictors of OS. This included
all relevant variables from the univariate analysis with a P <
.20 (donor, recipient age, pDC count) or previously known
risk factors (risk of the disease, grades II to IV acute GVHD). In
this analysis, both older age of recipient and low pDC pro-
portion proved to be independent predictive factors of worse
OS (P ¼ .02 and P ¼ .03, respectively) (Table 3).
P = .007
Figure 3. OS according to the low versus high pDC recovery groups deter-
mined at 100 days after allo-SCT. Solid lines indicate low pDC recovery group;
dashed lines, high pDC recovery group.
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It was previously shown that DCs recover quickly in the
peripheral blood of patients after allo-SCT [9] and that the
dynamics of their recovery depends on patient or graft
characteristics, conditioning regimen, or infections [15].
However, in our group of patients, only the occurrence of
grades II to IV acute GVHD independently impaired pDC re-
covery. Treatment with corticosteroids has also been shown
to efﬁciently deplete blood pDCs in transplant recipients
[16]. Because glucocorticoids represent the standard treat-
ment of grades II to IV acute GVHD in our institution, it is
possible that the drop in the pDC level at day 100 in our study
was at least partly due to the corticosteroids and not only to
acute GVHD itself. Thus, although the proportion of activated
pDCs to produce TNF-a and IFN-a was signiﬁcantly reduced
in patients with clinically severe grades II to IV acute GVHD,
as compared with patients without acute GVHD, this signif-
icance was lost in the same analysis done only in patients
without high-dose corticosteroids in the therapy. Previous
studies from our group showed a signiﬁcant increase of pDCs
in the intestinal mucosa and skin of patients with acute
GVHD compared with those without acute GVHD [17,18].
Therefore, a possible mechanism underlying the decrease of
pDCs in the blood of our patients with clinically signiﬁcant
acute GVHD may be the recruitment of pDCs from the pe-
ripheral blood to the affected tissues. On the other hand, a
tolerogenic potential of human pDCs by inducing regulatory
T cells and inhibiting acute GVHD has also been suggested
[19]. In this context, a reduced pDC level in the blood of
patients with clinically signiﬁcant acute GVHD could provide
evidence for the concept that resting pDCs in the blood are
tolerogenic and have the potential to prevent GVHD.Table 3
Multivariate Analysis of Predictors of OS
Risk Factor Relative Risk 95% CI P
Low pDC count 3.97 1.29-12.22 .02
Older age of recipient 5.22 1.16-23.44 .03
Donor type: MUD 2.29 .67-7.92 .19
Acute GVHD grades II-IV .65 .23-1.88 .43
High risk disease 1.21 .46-3.25 .69
MUD indicates matched unrelated donor.Given the central role of DCs in the immune system,
several previous human studies analyzed the relationship
between DC recovery after allo-SCT and long-term outcome
of patients, particularly GVHD and relapse [20]. Among
others, the peripheral blood pDC count at 3 months after
allo-SCT was shown to be an independent factor of OS [15].
In our study we allocated patients according to the me-
dian value of pDC proportion and obtained 2 comparable
groups. In the Kaplan-Meier analysis, the OS was signiﬁ-
cantly lower in the low pDC as compared with the high pDC
group, and this difference was conﬁrmed in the multivariate
analysis as well, together with a known factor of worse
survivaldolder age of the recipient. The worse survival of
patients in the lowpDC groupwasmostly due to signiﬁcantly
higher cumulative incidence of relapse-related mortality,
which suggested that a higher number of pDCs reconstituted
after transplantation might reduce relapse. Furthermore, a
couple of clinical reports of the relation of levels of DCs in the
blood with the development of GVHD yielded conﬂicting
results. Thus, peripheral blood low pDC count on day 28 after
allo-SCT independently predicted for both acute and chronic
GVHD in 1 study [21], whereas high pDC numbers at 14.5
months predicted chronic GVHD in another [22]. In addition,
a recent study demonstrated that pDCs and naive T cells in
bone marrow grafts were associated with survival after
unrelated-donor allogeneic hematopoietic SCT [23]. How-
ever, more functional studies are needed to decipher the
exact role of pDCs in antitumor immunity and GVHD.
In addition, the impact of antithymocyte globulin, type of
conditioning, and stem cell source on pDC recovery should
be investigated in other allo-SCT settings. In the meantime,
enumerating pDC count at day 100 after allo-SCT could serve
as a simple, fast, and reproducible indicator of adverse clin-
ical outcome of patients, in terms of relapse, death, and
GVHD. Monitoring pDC count could allow for early classiﬁ-
cation of patients according to the risk for these events and
for potential early therapeutic interventions to increase the
pDC number in the blood of patients to improve their out-
comes. Although the group of patients analyzed in our study
was rather heterogeneous regarding diagnoses and trans-
plant characteristics, precluding establishing the deﬁnitive
role and impact of the pDC subsets after allo-SCT, this and
similar investigations are important to further understand
the precise immunoregulatory properties of pDCs and to
pave the way for new targeted therapies in GVHD and he-
matological malignancies.
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